Akademik Veri Yönetim Sistemi
CLINICAL BIOCHEMISTRY, cilt.33, sa.1, ss.47-51, 2000 (SCI-Expanded)
Objectives: To investigate whether there is a relationship between serum 1,25 dihydroxy vitamin D-3 [1,25(OH)(2)D-3] which is an inhibitor of angiogenesis, concentrations and severity of diabetic retinopathy (DR). Design and methods: Serum 1,25(OH)(2)D-3, 25 hydroxy vitamin D [25(OH)D] and parathormone (PTH) concentrations were measured in diabetic patients (n = 66) and nondiabetic healthy subjects (n = 20). Results: The mean serum 1,25(OH)(2)D-3 concentration in diabetic patients was lower than that in nondiabetics (57.3 +/- 21.44 vs 89.4 +/- 18.01 pmol/L, p < 0.001); mean 1,25(OH)(2)D-3 concentrations fell with increasing severity of DR [being 63.4 +/- 17.26 pmol/L for background DR (BDR), 47.7 +/- 13.27 pmol/L for preproliferative DR (pre-PDR), and 43.1 +/- 19.45 pmol/L for proliferative DR (PDR)]. Compared with the control group, serum 25(OH)D concentrations were found to be decreased in diabetic patients (p < 0.001). There were negative correlations between 1,25(OH)(2)D-3 and age (r = -0.331, p < 0.01) and duration of diabetes (r = -0.255, p < 0.05). Conclusion: From these findings, it was found that there was an inverse relationship between the severity of the retinopathy, i.e., neovascularization, and serum 1,25(OH)(2)D-3 concentrations, being the lowest in PDR and the highest in diabetic patients without retinopathy (NDR) patients. The measurement of serum 1,25(OH)(2)D-3 concentrations might be helpful to predict severity of DR in patients with diabetes mellitus. Copyright (C) 2000 The Canadian Society of Clinical Chemists.